Pulmovant’s mosliciguat produced unusually large improvements across pulmonary vascular resistance, exercise capacity and cardiac strain in PH-ILD, giving Roivant a strong Phase 2 hand as the much larger PHrontier study tests whether those effects hold.
The U.S. Food and Drug Administration has approved Priovant Therapeutics’ LISRAYA, or brepocitinib, for adults with dermatomyositis, creating the first FDA-approved oral treatment for the rare systemic autoimmune disease. The decision converts positive Phase 3 VALOR data into Roivant Sciences’ first commercial opportunity for a drug that is also being developed across several other immune-mediated
Strong Phase 2 data put brepocitinib on a rare pivotal path in cutaneous sarcoidosis. Find out what this changes for clinicians and regulators.